The calcimimetic etelcalcetide attenuates pressure overload–induced cardiac hypertrophy in rats with and without chronic kidney disease

Key Points

• This research aims to investigate the effects of etelcalcetide on cardiac hypertrophy in rats, particularly in the context of chronic kidney disease.
• Utilized rat models with and without chronic kidney disease (CKD) to assess cardiac hypertrophy.
• Administered etelcalcetide (ET) to evaluate its impact on left ventricular hypertrophy (LVH).
• Monitored renal function and cardiac biomarkers, focusing on RAAS and FGF23 expression.
• ET effectively reduced left ventricular hypertrophy in both LVH and CKD/LVH groups.
• Cardioprotective effects were linked to modulation of the renin-angiotensin-aldosterone system (RAAS).
• Reduction in cardiac FGF23 expression was observed as a result of ET administration.